Free Trial

Extendicare (TSE:EXE) Sets New 1-Year High - Here's Why

Extendicare logo with Medical background

Extendicare Inc. (TSE:EXE - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$13.40 and last traded at C$13.33, with a volume of 7781 shares traded. The stock had previously closed at C$13.35.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EXE. Cormark raised Extendicare to a "moderate buy" rating in a research report on Wednesday, February 19th. BMO Capital Markets raised their price target on shares of Extendicare from C$11.00 to C$13.50 in a research report on Monday, March 3rd. Finally, TD Securities upped their price objective on Extendicare from C$10.50 to C$13.00 and gave the company a "hold" rating in a research report on Monday, March 3rd.

Get Our Latest Research Report on Extendicare

Extendicare Trading Up 1.9 %

The company has a debt-to-equity ratio of 283.02, a current ratio of 0.62 and a quick ratio of 0.98. The stock's 50-day moving average is C$12.99 and its two-hundred day moving average is C$11.16. The company has a market cap of C$1.17 billion, a P/E ratio of 17.93 and a beta of 1.26.

Extendicare Increases Dividend

The company also recently declared a monthly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Thursday, May 15th will be paid a $0.042 dividend. This is an increase from Extendicare's previous monthly dividend of $0.04. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Wednesday, April 30th. Extendicare's dividend payout ratio (DPR) is 61.20%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Recommended Stories

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines